MedTrace Logo

Isoquercetin in Sickle Cell Anemia

NCT04474626 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-01-11

No results posted yet for this study

Summary

This research study is being done to assess the safety and effectiveness of isoquercetin to reduce levels of soluble P-Selectin in patients with sickle cell disease. Isoquercetin is a naturally occurring flavonoid-or vitamin. You will find quercetin and isoquercetin in fruits and vegetables.

The names of the study drug involved in this study are/is:

\- Isoquercetin

Conditions

Interventions

DRUG

Isoquercetin

Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.

Sponsors & Collaborators

  • Quercegen Pharmaceuticals

    collaborator INDUSTRY

  • Jeffrey Zwicker, MD

    lead OTHER

Principal Investigators

  • Jeffrey Zwicker, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-31
Primary Completion
2022-12-31
Completion
2024-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04474626 on ClinicalTrials.gov